IMPORTANT SAFETY INFORMATION WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT RETACRIT®(epoetin alfa-epbx)? RETACRIT®may cause serious side effects that can lead to death, including: FOR PEOPLE WITH CANCER: Your tumor may grow faster and you may die sooner if you choose to take...
Retacrit(epoetin alfa-epbx)使用说明 Retacrit | epoetin alfa-epbx 2018年5月15日,美国食品和药物管理局批准Retacrit作为Epogen/Prorit的生物仿制药,用于治疗透析患者和非透析患者因慢性肾病(CKD)导致的贫血,艾滋病毒感染患者使用齐多夫定以及伴随骨髓抑制化疗的效果。...
美国FDA于2018年5月15日批准Hospira公司(Hospira Inc.,辉瑞Pfizer旗下子公司)的Retacrit(epoetin alfa-epbx)作为生物仿制药(biosimilar)用于治疗因多种原因引起的贫血,包括慢性肾病,癌症化疗,HIV感染者服用齐多夫定治疗等;也可用于外科手术前后以减少患者因手术过程中失血而导致的输血.夏训明...
Retacrit (epoetin alfa-epbx) Injection is an erythropoiesis-stimulating agent (ESA) indicated for treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis; zidovudine in patients with HIV-infection; the effects of concomitant myelosuppressive chemotherapy, ...
Retacrit(epoetin alfa-epbx) - Hospira Inc., a Pfizer Company Formulation typeStrength Multi-Dose Vial20,000 units/2 mL (10,000 units/mL) Multi-Dose Vial20,000 units/mL Single-Dose Vial10,000 units/mL Single-Dose Vial2,000 units/mL ...
Medications Epoetin alfa Epoetin alfa Share Brands Epogen•Procrit•Recormon•Eprex Side Effects Common Fatigue Diarrhea Dizziness Fever Headache Joint pains Nausea Vomiting Congestion Cough Nasal congestion Heart palpitations Paresthesia Loss of strength ...
While erythropoietin biosimilars have been approved by the EMA since 2007, the FDA's approval of epoetin alfa-epbx in 2018 marks the first erythropoietin biosimilar approved in the United States. Areas covered : In this article, we critically review the biology, clinical use, manufacturing, safety...
美国FDA于2018年5月15日批准Hospira公司(Hospira Inc.,辉瑞Pfizer旗下子公司)的Retacrit(epoetin alfa-epbx)作为生物仿制药(biosimilar)用于治疗因多种原因引起的贫血,包括慢性肾病,癌症化疗,HIV感染者服用齐多夫定治疗等;也可用于外科手术前后以减少患者因手术过程中失血而导致的输血.doi:CNKI:SUN:GDYX.0.2018-03-...
IntroductionThis double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease (ESKD) and anemia who were receiving epoetin alfa ...